Clene Announces Additional CNM-Au8 Biomarker Data Supporting Potential NDA Filing for Upcoming In-Person FDA Meeting GlobeNewswire January 12, 2026 The FDA has granted an in-person Type C meeting during the first quarter of 2026 New independent analyses across large observational ALS cohorts demonstrate that modest (~10%) NfL reductions are significantly associated with lower mortality risk, […]

ORIC(R) Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones GlobeNewswire January 12, 2026 Announced rinzimetostat (ORIC-944) Phase 1b data that continue to demonstrate potential best-in-class efficacy and safety in mCRPC; selected provisional RP2Ds and initiated dose optimization in combination with AR inhibitors Presented potential best-in-class enozertinib Phase 1b data demonstrating highly competitive systemic

Kailera Therapeutics Announces First Participants Randomized in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide (KAI-9531) GlobeNewswire January 12, 2026 – Ribupatide (KAI-9531) aims to address critical need for greater weight loss, especially for people living with a BMI of 35 kg/m2 or greater – – KaiNETIC program includes three Phase

Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron(R) Through Phase 2b Development GlobeNewswire January 12, 2026 Pricing of $12.5 Million Registered Direct Offering & Concurrent Private Placement Offerings priced at-the-market under Nasdaq rules ALPHARETTA, Ga., Jan. 12, 2026 (GLOBE NEWSWIRE) — Dogwood Therapeutics, Inc. (NASDAQ: DWTX) (“DWTX” or “Company”), a

Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance GlobeNewswire January 12, 2026 SALT LAKE CITY, Jan. 12, 2026 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced select unaudited preliminary results for the

Disc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026 GlobeNewswire January 12, 2026 Bitopertin was awarded the Commissioner's National Priority Review Voucher (CNPV) and NDA is currently under FDA review Updated data from the Phase 2 study of DISC-0974 in patients with myelofibrosis (MF) and anemia expected in H2 2026, followed

Xenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare Conference GlobeNewswire January 12, 2026 Phase 3 X-TOLE2 topline data for azetukalner in FOS expected March 2026 followed by anticipated NDA submission in H2 2026 Five additional Phase 3 azetukalner studies continuing to enroll patients in multiple indications in epilepsy and neuropsychiatry; Phase 3

NewtekOne, Inc. to Report Fourth Quarter 2025 Results and Host a Conference Call on Thursday, January 29, 2026 GlobeNewswire January 12, 2026 BOCA RATON, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) — NewtekOne, Inc. (the “Company”) (NASDAQ: NEWT) will report its fourth quarter 2025 financial results after the market closes on Thursday, January 29, 2026. A

Alignment Healthcare Reports 31% Year-Over-Year Membership Growth to 275,300 as of Jan. 1, 2026 GlobeNewswire January 12, 2026 Guides year-end 2026 health plan membership range of 290,000 to 296,000. Announces its expectation that consensus adjusted EBITDA of approximately $145 million in 2026 will be within its full-year 2026 guidance range. Reaffirms its full-year 2025 guidance

Latin Metals Positions for a Catalyst-Driven 2026 with Gold and Copper Exposure GlobeNewswire January 12, 2026 VANCOUVER, British Columbia, Jan. 12, 2026 (GLOBE NEWSWIRE) — Latin Metals Inc. (“Latin Metals” or the “Company“) (TSXV: LMS) (OTCQB: LMSQF) is pleased to provide shareholders with an overview of project advancement achieved during 2025 and the exploration and